A DNA test could help match patients with psychiatric medications, potentially reducing the long and frustrating trial-and-error process.
SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six ...
SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical ...
Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
MASON, Ohio — Finding the right medication to treat mental health is often a frustrating game of trial and error between a patient and their healthcare provider. A ...
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 ...
Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results